- Sections
- A - Nécessités courantes de la vie
- A61K - Préparations à usage médical, dentaire ou pour la toilette
- A61K 39/04 - Mycobacterium, p.ex. Mycobacterium tuberculosis
Détention brevets de la classe A61K 39/04
Brevets de cette classe: 1002
Historique des publications depuis 10 ans
73
|
66
|
78
|
74
|
67
|
63
|
67
|
56
|
47
|
19
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Propriétaires principaux
Proprétaire |
Total
|
Cette classe
|
---|---|---|
Glaxosmithkline Biologicals S.A. | 1701 |
39 |
Statens Serum Institut | 95 |
21 |
Access to Advanced Health Institute | 75 |
20 |
International AIDS Vaccine Initiative, Inc. | 51 |
19 |
Vakzine Projekt Management GmbH | 32 |
18 |
Wisconsin Alumni Research Foundation | 3774 |
16 |
Immodulon Therapeutics Limited | 44 |
16 |
The Regents of the University of California | 18943 |
15 |
Longhorn Vaccines and Diagnostics, LLC | 82 |
15 |
Rutgers, The State University of New Jersey | 1776 |
13 |
Glaxo Group Limited | 4496 |
12 |
The Johns Hopkins University | 5377 |
12 |
Archivel Farma, S.L. | 15 |
12 |
Infectious Disease Research Institute | 46 |
12 |
Institut Pasteur | 798 |
11 |
The General Hospital Corporation | 4517 |
10 |
Aeras Global TB Vaccine Foundation | 25 |
10 |
Albert Einstein College of Medicine, Inc. | 528 |
10 |
The UAB Research Foundation | 629 |
10 |
The Trustees of the University of Pennsylvania | 4122 |
9 |
Autres propriétaires | 702 |